Prothena (PRTA)

Prothena (PRTA) Stock Price & Analysis


PRTA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$28.99 - $79.65
Previous Close$51
Average Volume (3M)375.59K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$660.45M
Total Debt (Recent Filing)$3.45M
Price to Earnings (P/E)-18.4
Nov 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding53,535,300
10 Day Avg. Volume449,077
30 Day Avg. Volume375,587
Standard Deviation0.26
Financial Highlights & Ratios
Price to Book (P/B)4.69
Price to Sales (P/S)679.35
Price to Cash Flow (P/CF)N/A
P/FCF Ratio88.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside86.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $28.99 and its highest was $79.65 in the past 12 months.
    What is Prothena’s market cap?
    Currently, no data Available
    When is Prothena’s upcoming earnings report date?
    Prothena’s upcoming earnings report date is Nov 07, 2023 which is in 43 days.
      How were Prothena’s earnings last quarter?
      Prothena released its earnings results on Aug 03, 2023. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.933 by -$0.097.
        Is Prothena overvalued?
        According to Wall Street analysts Prothena’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Prothena pay dividends?
          Prothena does not currently pay dividends.
          What is Prothena’s EPS estimate?
          Prothena’s EPS estimate is -$0.32.
            How many shares outstanding does Prothena have?
            Prothena has 53,535,300 shares outstanding.
              What happened to Prothena’s price movement after its last earnings report?
              Prothena reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.933. Following the earnings report the stock price went down -7.305%.
                Which hedge fund is a major shareholder of Prothena?
                Among the largest hedge funds holding Prothena’s share is Maple Rock Capital Partners Inc.. It holds Prothena’s shares valued at 16M.


                  Prothena Stock Smart Score

                  The Prothena stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.


                  Top 5 ETFs holding PRTA

                  Market Value
                  Smart Score
                  Vanguard Health Care ETF
                  Schwab U.S. Broad Market ETF
                  Fidelity Nasdaq Composite Index ETF
                  Vanguard U.S. Momentum Factor ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold PRTA. The ETFs are listed according to market value of PRTA within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Minerva Neurosciences
                  Kura Oncology

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis